SET domain-containing protein 7/9 (SET7/9) is a histone methyltransferase that monomethylates lysine 4 of histone H3, which generates a specific tag for epigenetic transcriptional activation. It plays a role in the transcriptional activation of tumor suppressor p53 in response to DNA damage, as well as the transcription factor TAF10. (R)-PFI-2 is a potent, cell-permeable inhibitor of SET7/9 (IC = 2 nM) that demonstrates greater than 1,000-fold selectivity over a panel of 18 other methyltransferases. (S)-PFI-2, the inactive enantiomer, is 500-fold less potent (IC = 1 µM) and may serve as a negative control. See the Structural Genomics Consortium (SGC) website for more information.
(S)-PFI-2 (hydrochloride) is an inhibitor of lysine methyltransferase SETD7 and is approximately 500-fold more active than its enantiomer (R)-PFI-2. (R)-PFI-2 is a cofactor-dependent and substrate-competitive inhibitor. (R)-PFI-2 can occupy the substrate peptide binding groove of SETD7 (including the catalytic lysine binding channel) and interact with the cofactor The donor methyl group is in direct contact. However, (S)-PFI-2 was not observed to have the same interaction as (R)-PFI-2.
IC50&Target
Lysine methyltransferase SETD7
体外研究
(S) PFI-2 (hydrochloride) (10 μM; 2 h) did not cause a dose-dependent increase in nuclear YAP in MCF7 cells, nor did it enhance the expression of YAP target genes AREG and CYR61; And (R) - PFI-2 can increase the expression of YAP, AREG, and CYR61 [1].
分子式
C23H25F4N3O3S.HCl
分子量
535.98
CAS号
1627607-88-8
中文名称
(S)-PFI-2 (hydrochloride)
运输条件
Room temperature in continental US; may vary elsewhere.
[1]. Niu Y, et al. Revealing inhibition difference between PFI-2 enantiomers against SETD7 by molecular dynamics simulations, binding free energy calculations and unbinding pathway analysis. Sci Rep. 2017 Apr 18;7:46547.